Abstract 315P
Background
Based on PRIMA and PRIME, Niraparib is approved by FDA and NMPA for first-line maintenance of OC regardless of biomarker status. Niraparib is widely used in China, while its efficacy and safety in real world remains to be verified. The purpose of this study was to evaluate the efficacy and safety of niraparib as maintenance in newly diagnosed advanced OC.
Methods
We retrospectively collected patients with pathologically confirmed diagnosis of OC, who received niraparib as first-line maintenance therapy at the Department of Gynecology, Tianjin Cancer Hospital between January 2021 and December 2022. Demographics, baseline characteristics, clinical outcomes and adverse events were collected. The history of niraparib use, including the time from the end of chemotherapy to the start of maintenance therapy, the starting dose, and the stable dose used after 3 months, were also collected.
Results
102 patients were enrolled. The median age was 58 years and 84.3% were FIGO stage III/IV. 18.6% BRCAmut, 58.8% BRCAwt and 22.5% BRCAunkown, while 36.3% HRD deficient, 12.7% HRD proficient and 51% HRD unkown. 53.9% received NACT, 76.5% were R0 after surgery and 62.7% were CR after chemotherapy. Median follow-up was 10.5m. In the ITT population, the mPFS was not reached, with a 24-month PFS rate of 52.5%. The mPFS of BRCAmut, BRCAwt, and BRCAunknown was not reached, 14.4 and 14.6m, respectively. The 24-month PFS rates were 90%, 48.4% and 37.9%, respectively. The mPFS of HRD deficient and HRD proficient were both not reached. 84.3% of patients experienced any grade TEAEs, while 17.6% experienced TEAEs of grade ≥3. TEAEs leading to treatment interruption was 36.3%, leading to dose reduction was 29.4%, leading to discontinuation was 0.98%. The most common hematological TEAEs were platelet count decreased (28.4%) while grade ≥3 TEAEs was 5.9%, white blood cell count decreased (20.6%) and neutrophil count decreased (26.5%). Non-hematologic TEAEs were nausea (31.4%), fatigue (30.4%) and insomnia (21.6%).
Conclusions
In the real world, niraparib maintenance in newly diagnosed advanced OC is effective and safe, which was consistent with previous RCT. More clinical related factors affecting prognosis will be further explored.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Tianjin Medical University Cancer Institute & Hospital.
Funding
Committee of Gynecological Oncology, Tianjin anti-cancer association.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
571P - Dacomitinib in treatment-naïve EGFR-mutant NSCLC patients with multiple brain metastases: Initial efficacy and safety data from a phase II study
Presenter: Yongfeng Yu
Session: Poster Display
Resources:
Abstract
572P - Multivariable five-year survival prediction model for prognosing patients with EGFR-mutated NSCLC treated with EGFR-TKIs
Presenter: Qi-An Wang
Session: Poster Display
Resources:
Abstract
573P - LUMINATE-103: Real-world treatment patterns and outcomes of patients (pts) with epidermal growth factor receptor mutant (EGFR MU), non-squamous (NSQ) locally advanced/metastatic non-small cell lung cancer (a/mNSCLC): Pooled analysis of large US electronic health record (EHR) datasets
Presenter: Byoung Chul Cho
Session: Poster Display
Resources:
Abstract
574P - Efficacy and safety of dacomitinib in treatment-naïve patients with advanced NSCLC harboring uncommon EGFR mutations
Presenter: Lin Wu
Session: Poster Display
Resources:
Abstract
575P - Efficacy and safety of dacomitinib in treatment-naïve patients with advanced NSCLC and brain metastasis: A multicenter cohort study
Presenter: Puyuan Xing
Session: Poster Display
Resources:
Abstract
576P - Clonality of both EGFR and co-occurring TP53 mutations affect the treatment efficacy of the third-generation EGFR-TKIs in advanced-stage EGFR-mutant non-small cell lung cancer
Presenter: Wen Feng Fang
Session: Poster Display
Resources:
Abstract
577P - A study of the efficacy and safety of amivantamab in EGFR exon 20 insertion (E20I) mutations in NSCLC
Presenter: Daeho Choi
Session: Poster Display
Resources:
Abstract
578P - Tyrosine kinase inhibitor treatment of elderly patients with epidermal growth factor receptor mutated advanced non-small cell lung cancer: A multi-institute retrospective study
Presenter: Ling-Jen Hung
Session: Poster Display
Resources:
Abstract
579P - Real-world study of dacomitinib as first-line treatment for patients with EGFR-mutant non-small cell lung cancer
Presenter: Ji Eun Shin
Session: Poster Display
Resources:
Abstract
580P - Efficacy and safety of dacomitinib as first-line treatment for advanced non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor <italic>(EGFR)</italic> 21L858R mutation: A multicenter, ambispective, consecutive case-series study
Presenter: Shouzheng Wang
Session: Poster Display
Resources:
Abstract